biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Midatech at $1.0475

<< Previous

Bullboard Posts

Next >>

Comment by emmitfitzhumeon Dec 31, 2022 2:13pm

99 Views

Post# 35198545

RE:RE:RE:RE:RE:RE:RE:Midatech at $1.0475

"By obsessively fearing dilution so much BTI has been slow-walked into catastrophic dilution."

Even POF can admit this is catastrophic.

This is an unmitigated disaster for shareholders. JD is correct, Rathjen walks away with a sweet deal while turning her back on shareholders and leaving them with what amounts to nothing.

I would also like to know more about the implications of a "no" vote, and if there is any time or flexibility with the Lind debt.